Amgen Inc (AMGN) Sustained Profitability Outlook

Amgen reported USD figures for 2025 with revenue of about $36.75 billion, EBIT of $9.08 billion, and net income of $7.71 billion. Revenue grew roughly 10% year over year, showing steady expansion in its core therapeutic areas.

Depreciation and amortization totaled $5.17 billion, while capital expenditure was $1.86 billion, leaving a free‑cash‑flow proxy of $11.12 billion. These results indicate strong profitability and modest reinvestment needs.

Margins remain robust on a trailing basis, with gross margin at 73.3% and operating margin at 25.43%. Such efficiency suggests the company converts a large share of revenue into operating profit, reinforcing its ability to fund growth internally.

Return on equity stands at 96.65%, highlighting exceptional capital efficiency. Interest coverage was not provided, limiting visibility on debt servicing capacity.

At a market price of $349.92, the shares trade below the DCF’s central estimate range, implying the market discounts future cash generation. The valuation suggests investors are cautious about sustaining current returns despite strong recent performance.

The DCF base case implies potential upside if cash flows hold steady, while persistently high margins could extend strong free‑cash‑flow generation. The market appears to price in moderation rather than continued strength.